Seeking Alpha
28 Sept 2026, 18:43 UTC · 1h ago
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
Verdict
Headline takes no side. We score MIRM +0.50 — strongly bullish.
- Expected · MIRM
+0.50strongly bullish
−1 bearish0bullish +1More positive than 71% of ticker scores this week


